bluebird bio, Inc. (NASDAQ:BLUE) Director Daniel Lynch Sells 4,000 Shares

bluebird bio, Inc. (NASDAQ:BLUE) Director Daniel Lynch sold 4,000 shares of bluebird bio stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $109.09, for a total value of $436,360.00. Following the completion of the sale, the director now owns 4,808 shares in the company, valued at $524,504.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Daniel Lynch also recently made the following trade(s):

  • On Tuesday, June 20th, Daniel Lynch sold 2,500 shares of bluebird bio stock. The stock was sold at an average price of $120.03, for a total value of $300,075.00.
  • On Tuesday, June 6th, Daniel Lynch sold 2,263 shares of bluebird bio stock. The shares were sold at an average price of $100.14, for a total value of $226,616.82.
  • On Thursday, May 25th, Daniel Lynch sold 2,000 shares of bluebird bio stock. The shares were sold at an average price of $80.00, for a total value of $160,000.00.
  • On Thursday, April 27th, Daniel Lynch sold 1,000 shares of bluebird bio stock. The shares were sold at an average price of $90.01, for a total value of $90,010.00.
  • On Tuesday, April 25th, Daniel Lynch sold 2,000 shares of bluebird bio stock. The stock was sold at an average price of $86.75, for a total value of $173,500.00.

bluebird bio, Inc. (NASDAQ BLUE) traded up 1.41% during midday trading on Monday, reaching $97.15. The company had a trading volume of 277,615 shares. The stock’s 50 day moving average price is $97.43 and its 200-day moving average price is $83.86. The firm’s market capitalization is $3.98 billion. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $123.75.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.76) by $0.08. The business had revenue of $6.83 million during the quarter, compared to the consensus estimate of $1.51 million. bluebird bio had a negative net margin of 2,402.03% and a negative return on equity of 35.17%. On average, equities research analysts anticipate that bluebird bio, Inc. will post ($6.70) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “bluebird bio, Inc. (NASDAQ:BLUE) Director Daniel Lynch Sells 4,000 Shares” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://sportsperspectives.com/2017/07/17/daniel-lynch-sells-4000-shares-of-bluebird-bio-inc-blue-stock-updated-updated.html.

A number of analysts have recently weighed in on the company. BTIG Research reiterated a “buy” rating and set a $112.00 price target on shares of bluebird bio in a research report on Thursday, June 1st. Maxim Group raised bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Friday, June 2nd. Wedbush reaffirmed an “outperform” rating on shares of bluebird bio in a research note on Tuesday, June 6th. Zacks Investment Research raised bluebird bio from a “hold” rating to a “buy” rating and set a $118.00 price objective for the company in a research note on Tuesday, July 4th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. bluebird bio currently has an average rating of “Buy” and an average price target of $100.02.

A number of large investors have recently bought and sold shares of BLUE. Martingale Asset Management L P boosted its stake in bluebird bio by 0.6% in the first quarter. Martingale Asset Management L P now owns 17,008 shares of the biotechnology company’s stock worth $1,547,000 after buying an additional 100 shares during the last quarter. Legal & General Group Plc boosted its stake in bluebird bio by 2.6% in the first quarter. Legal & General Group Plc now owns 13,944 shares of the biotechnology company’s stock worth $1,272,000 after buying an additional 357 shares during the last quarter. First Mercantile Trust Co. boosted its stake in bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock worth $263,000 after buying an additional 365 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in bluebird bio by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,220 shares of the biotechnology company’s stock worth $4,210,000 after buying an additional 540 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares during the last quarter.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply